Federal Register / Vol. 86, No. 166 / Tuesday, August 31, 2021 / Notices 48711 

when requesting a copy of their client’s 

case file. 

8. UC Legal Information (Form L–4): 

This instrument is used by case 

managers to document, as applicable, 

referrals to the Office on Trafficking in 

Persons, meetings between the UC and 

their legal service provider or attorney 

of record, the provision of ORR’s Legal 

Resource Guide to the UC, information 

about the UC’s legal service provider or 

attorney of record, immigration and 

administrative hearings, and provision 

of the Notice of Placement in a 

Restrictive Setting to the UC. The 

instrument also includes an area to 

upload legal documents. 

9. Legal Service Provider Record 

(Form L–6): This instrument is used by 

case managers to create a record 

containing certain information and 

documents that ORR makes accessible 

to ORR-funded legal service providers 

without requiring a formal records 

request. 

10. Motion for Change of Venue (Form 

L–7): This instrument is used by case 

managers to file a motion for change of 

venue when a UC is transferred or 

discharged to a new immigration court 

jurisdiction. 

11. Post Legal Status Plan (Form L–8): 

This instrument is used by case 

managers to create and obtain FFS 

Supervisor approval for a plan for UC 

expected to obtain legal status, at which 

time the UC must be released from ORR 

custody. 

Proposed revisions: 

• Replace the term ‘‘unaccompanied 

alien child (UAC)’’ with 

‘‘unaccompanied child (UC)’’ 

throughout the instruments in this 

collection. Note that the screenshots of 

UC Path instruments attached to this 

memo do not reflect this change because 

it has not yet been developed in the 

system. However, the revision in 

terminology will be made before the 

system is launched. 

• Remove the term ‘‘alien’’ from the 

title of this information collection and 

revise it to read ‘‘Legal Services for 

Unaccompanied Children.’’ 

Respondents: ORR grantee and 

contractor staff, UC, parents/legal 

guardians of UC, attorneys of record, 

and legal service providers. 

ANNUAL BURDEN ESTIMATES

Instrument 

Annual total 

number of 

respondents 

Annual total 

number of 

responses per 

respondent 

Average 

burden 

minutes per 

response 

Annual total 

burden hours 

Legal Service Provider List for UC in ORR Care (Form LRG–5/5s) .............. 216 556.0 15 30,024 

Request for a Flores Bond Hearing (Form LRG–7/7s) ................................... 216 0.2 10 7 

Motion to Request a Bond Hearing—Secure or Staff Secure Custody (Form 

LRG–8A) ...................................................................................................... 8 3.0 10 4 

Motion to Request a Bond Hearing—Non-Secure Custody (Form LRG–8B) 208 0.1 10 3 

Request for Specific Consent to Juvenile Court Jurisdiction (Form L–1) ....... 40 1.0 15 10 

Specific Consent Request Case Summary (Form L–2) .................................. 216 0.2 20 14 

Notice of Attorney Representation (Form L–3) ............................................... 13,000 1.0 15 3,250 

UC Legal Information (Form L–4) .................................................................... 216 241.0 60 52,056 

Legal Service Provider Record (Form L–6) ..................................................... 216 241.0 5 4,338 

Change of Venue (Form L–7) ......................................................................... 216 208.0 10 7,488 

Post Legal Status Plan (Form L–8) ................................................................. 216 24.0 15 1,296 

Estimated Annual Burden Hours Total ..................................................... ........................ ........................ ........................ 98,490 

Authority: 6 U.S.C. 279; 8 U.S.C. 

1232; Flores v. Reno Settlement 

Agreement, No. CV85–4544–RJK (C.D. 

Cal. 1996). 

Mary B. Jones, 

ACF/OPRE Certifying Officer. 

[FR Doc. 2021–18658 Filed 8–30–21; 8:45 am] 

BILLING CODE 4184–45–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Community Living 

Intent To Award a Supplement for the 

Lifespan Respite Program: Special 

Projects To Strengthen Program 

Development, Implementation and 

Sustainability 

ACTION: Notice. 

SUMMARY: The Administration for 

Community Living (ACL) announces the 

intent to award a single-source 

supplement to the current cooperative 

agreement held by the Center for Health 

Policy Development. 

FOR FURTHER INFORMATION CONTACT: For 

further information or comments 

regarding this program supplement, 

contact Lori Stalbaum, U.S. Department 

of Health and Human Services, 

Administration for Community Living, 

Administration on Aging, Office of 

Supportive and Caregiver Services: 

telephone (202) 795–7444; email 

lori.stalbaum@acl.hhs.gov. 

SUPPLEMENTARY INFORMATION: The 

primary objective of this project is to 

complement the work of the Lifespan 

Respite Technical Assistance and 

Resource Center (TARC) funded in FY 

2020 (42 U.S.C. 300ii–2: National 

Lifespan Respite Resource Center) and, 

based on the forthcoming National 

Family Caregiving Strategy, focus on 

improving access to respite services, 

workforce capacity, and the role of 

natural supports, which will be a likely 

focus of attention nationwide following 

the dissemination of the Family 

Caregiving Advisory Council’s National 

Family Caregiving Strategy. 

1. Workforce Development: Develop, 

test and scale a respite workforce 

recruitment, training and retention 

program to better meet the respite needs 

of culturally diverse, urban, suburban, 

rural, or frontier families, particularly in 

light of the impact of the COVID–19 

pandemic on the workforce; 

2. State-based respite planning: 

Develop and field test a state-based 

framework and roadmap for respite 

system planning and development, 

which ties to the forthcoming National 

Family Caregiving Strategy; and 

3. Natural supports: Enhance 

approaches to help caregivers and 

families develop or strengthen their own 

natural support systems to include 

respite and other supports 

The original FY 2020 award was in 

the amount of $562,737 for a three-year 

fully funded project. The administrative 

supplement for FY 2021 will be in the 

amount of $183,000, bringing the total 

award for the project to $745,737. 


khammond on DSKJM1Z7X2PROD with NOTICES
48712 Federal Register / Vol. 86, No. 166 / Tuesday, August 31, 2021 / Notices 

The additional funding will not be 

used to begin new projects, but to 

expand existing activities under the 

existing grant. Specifically, 

supplemental funds will be used to: 

1. Increase the number of states that 

will participate in the upcoming pilot 

project to field test a competency-based, 

entry-level respite provider-training 

curriculum and recruitment campaign. 

This also includes the option to request 

additional funding for increased 

administrative and management 

oversight; the provision of stipends, if 

necessary; and increased technical 

assistance to the pilot states. 

2. Enhance documentation and 

reporting on the pilot project, which 

could include reports, journal articles, 

or blogs on pre- and post-pilot work. For 

example, topics may include, but are 

not limited to: 

a. Detailing the methodology for 

developing the core competencies being 

piloted from conception to pilot 

implementation; and 

b. Documenting state successes as a 

part of the pilot program and/or 

detailing findings, positive or negative, 

learned from the one-year pilot. 

3. Expand/enhance the respite care 

tracking (mapping) system that will be 

available to state program policy 

personnel to allow them ready access to 

the findings of the state scans of respite 

programs and services and build on case 

studies being developed under this 

grant program. 

4. Expand and enhance the planned 

communication and information 

dissemination strategy to reach larger 

audiences of potential users of the 

materials developed under this project. 

Program Name: Lifespan Respite Care 

Program: Promoting Best Practices, 

Building State Capacity. 

Recipient: Center for Health Policy 

Development. 

Period of Performance: The 

supplement award will be issued in the 

second year of this three-year, fully 

funded, project scheduled to be 

completed on September 29, 2023. 

Total Award Amount: $562,737 in FY 

2020. 

Award Type: Cooperative Agreement 

Supplement. 

Statutory Authority: The statutory 

authority for grants under this program 

announcement is contained in Title 

XXIX of the Public Health Service Act 

(42 U.S.C. 300ii–1: Lifespan Respite 

Care Grants and Cooperative 

Agreements), as amended by the Public 

Health Service Act Public Law 109–442. 

(Catalog of Federal Domestic Assistance 

93.072). 

Basis for Award: The Lifespan Respite 

Care Program: Special Projects to 

Strengthen Program Development, 

Implementation and Sustainability is 

currently funded to carry out the 

objectives of this project for the period 

of September 30, 2020 through 

September 29, 2023. Since project 

implementation began in late 2020, the 

grantee has accomplished a great deal. 

The supplement will enable the grantee 

to carry their work even further, 

reaching more states with workforce 

development assistance, information 

dissemination, direct technical 

assistance and tracking of state 

innovations and advancements in 

respite service design and delivery. The 

additional funding will not be used to 

begin new projects or activities. 

Dated: August 25, 2021. 

Alison Barkoff, 

Acting Administrator and Assistant Secretary 

for Aging. 

[FR Doc. 2021–18748 Filed 8–30–21; 8:45 am] 

BILLING CODE 4154–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2021–N–0762] 

Revocation of Authorization of 

Emergency Use of Certain Medical 

Devices During COVID–19; Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing the 

revocation of 15 Emergency Use 

Authorizations (EUAs) (the 

Authorizations), including 12 

Authorizations for decontamination 

systems for personal protective 

equipment, 1 Authorization for a 

bioburden reduction system for personal 

protective equipment, and 2 umbrella 

Authorizations for certain imported, 

non-NIOSH (National Institute of 

Occupational Safety and Health)- 

approved disposable respirators. FDA 

revoked the Authorizations for the 

decontamination and bioburden 

reduction systems for personal 

protective equipment on June 30, 2021, 

under the Federal Food, Drug, and 

Cosmetic Act (FD&C Act) as requested 

by each Authorization holder. FDA 

revoked the umbrella Authorizations 

issued to manufacturers and other 

stakeholders of imported non-NIOSH 

approved filtering facepiece respirators 

manufactured in China (China FFR 

Authorization), and to manufacturers 

and other stakeholders of imported nonNIOSH approved filtering facepiece 

respirators (Imports FFR Authorization) 

on June 30, 2021, under the FD&C Act. 

The revocations, which each include an 

explanation of the reasons for the 

revocation, are reprinted in this 

document. 

DATES: The Authorizations for the 

decontamination and bioburden 

reduction systems are revoked as of June 

30, 2021. The Authorizations for the 

China FFR Authorization and Imports 

FFR Authorization are revoked as of 

July 6, 2021. 

ADDRESSES: Submit written requests for 

a single copy of the revocations to the 

Office of Counterterrorism and 

Emerging Threats, Food and Drug 

Administration, 10903 New Hampshire 

Ave, Bldg. 1, Rm. 4338, Silver Spring, 

MD 20993–0002. Send one selfaddressed adhesive label to assist that 

office in processing your request or 

include a Fax number to which the 

revocation may be sent. See the 

SUPPLEMENTARY INFORMATION section for 

electronic access to the revocations. 

FOR FURTHER INFORMATION CONTACT: 

Michael Mair, Office of 

Counterterrorism and Emerging Threats, 

Food and Drug Administration, 10903 

New Hampshire Ave., Bldg. 1, Rm. 

4340, Silver Spring, MD 20993–0002, 

301–796–8510 (this is not a toll-free 

number). 

SUPPLEMENTARY INFORMATION: 

I. Background 

Section 564 of the FD&C Act (21 

U.S.C. 360bbb–3) allows FDA to 

strengthen the public health protections 

against biological, chemical, nuclear, 

and radiological agents. Among other 

things, section 564 of the FD&C Act 

allows FDA to authorize the use of an 

unapproved medical product or an 

unapproved use of an approved medical 

product in certain situations. Notice of 

the issuance of the Authorizations was 

published in the Federal Register as 

follows, as required by section 564(h)(1) 

of the FD&C Act: (1) Published June 5, 

2020 (85 FR 34638) for Imports FFR 

Authorization (Certain Imported, NonNIOSH-Approved Disposable Filtering 

Facepiece Respirators) issued March 24, 

2020; China FFR Authorization (Certain 

Non-NIOSH-Approved Disposable 

Filtering Facepiece Respirators 

Manufactured in China) issued April 3, 

2020; and STERIS Corporation for the 

STERIS Sterilization Systems (STERIS 

V–PRO 1 Plus, maX, and maX2 Low 

Temperature Sterilization Systems) 

issued April 9, 2020; (2) published July 

14, 2020 (85 FR 42407) for Advanced 

Sterilization Products, Inc. for the ASP 

STERRAD Decontamination Systems 

issued April 11, 2020; Stryker 


khammond on DSKJM1Z7X2PROD with NOTICES